Study details
Enrolling now
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
AbbVie
NCT IDNCT06524635ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
60
Study length
about 2.5 years
Ages
18–75
Locations
2 sites in CA, MI
About this study
This trial is testing a treatment called lutikizumab for people with hidradenitis suppurativa (HS) or atopic dermatitis (AD). Participants will receive subcutaneous injections of lutikizumab and have regular visits, blood tests, and biomarker collections. It duration is expected to last up to 30 weeks.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Lutikizumab
PhasePhase 2
DrugLutikizumab
Routesubcutaneous
Primary goalNumber of Participants With Adverse Events (AEs)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
monoclonal antibody
Drug routes
subcutaneous
Endpoints
Primary: Number of Participants With Adverse Events (AEs)
Body systems
Dermatology